References

1. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563-2570.
   
   
2. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106:135-140.
   
   
3. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clinl Pharmacol Ther. 2007;83(3):460-470.
   
   
4. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of pharmacogenetic-based dosing of warfarin in patients with atrial fibrillation. Ann Intern Med. 2009;150:73-83.
   
   
5. Evans A, Davis S, Kilpatrick C, Gerraty R, Campbell D, Greenberg P. The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. J Clin Neurosci. 2002;9(3):268-272.
   
   
6. Fanikos J, Grasso-Correnti N, Shah R, Kucher N, Goldhaber SZ, Major bleeding complications in a specialized anticoagulation service. Am J Cardiol. 2005;96:595-598.
   
   
7. Gage BF, Eby C, Johnson J, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-331.
   
   
8. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902.
   
   
9. International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. New Engl J Med. 2009;360(8):753-764.
   
   
10. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77(1):1-16.
    
    
11. Lenzini PA, Grice GR, Milligan PE, et al. Optimal initial dose adjustment of warfarin in orthopedic patients. Ann Pharmacother. 2007;41:1798-1804.
    
    
12. McWilliam A, Letter R, Nardinelli C. Health care savings from personalized medicine using genetic testing: the case of warfarin. working paper 06-23 AEI-Brookings Joint Center for Regulatory Studies. Nov 2006. 
    
    
13. Perez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood. 2009;113:4977-4979.
    
    
14. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med. 2005;352:2285-2293.
    
    
15. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7(2):97-104.
    
    
16. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response of warfarin during initial anticoagulation. New Engl J Med. 2008;358(10):999-1008.
    
    
17. Suttie JW. The biochemical basis of warfarin therapy. Adv Exp Med Biol. 1987;214:3-16.
    
    
18. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: Current status and future challenges. Pharmacogenomics J. 2007;7:99-111.
    
    
19. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 200514:1745-1751.